

## **CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS**

Manuscript page number (Without Figures): 12 Rate: 6.2 CNY per page

Editing Fee: 74.4 CNY

Figure count: <u>3</u> Figure handling time: <u>60</u> min Rate: <u>1 CNY per min</u>

Editing Fee: <u>60</u> CNY

XML and PDF converting time: 60 min Rate: 1 CNY per min

Editing Fee: 60 CNY

Manuscript word count: 2471

Total Editing Fee: <u>194.4</u> CNY

Scientific Editor: Ya-Juan Ma

Date of signature: <u>05/25/2022</u> (month/day/year)

Item No.		Comments
	Specific items for verification	Yes=[Y]
		No= [N]
	General Information of the Manuscript	
	Name of journal: World Journal of Clinical Cases	
	Manuscript NO.: 76422	
	Column: Case Report	
1	Title: Macular Hole Following Phakic Intraocular Lens	<b>1</b> 2/1
1	Implantation: a Case Report	[Y]
	Authors: Xue-jing Li, Jia-liang Duan, Jing-xue Ma and Qing-li	
	Shang	
	<b>Reviewer code:</b> 06271151, and 06254068	
	<b>First decision:</b> 2022-04-08 08:01	
2	Editorial Office's Comments	[Y]



# Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Science Editor: Remind Revision at 2022-04-16 08:18 Company Editor-in-Chief: I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Clinical Cases, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before final acceptance, uniform presentation should be used for figures showing the same or similar contents; for example, "Figure 1 Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...". Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the



	Collections account data in formation of the later of the	
	following copyright information to the bottom right-hand side of	
	the picture in PowerPoint (PPT): Copyright ©The Author(s) 2022.	
3	The fixed headings are copied.	[Y]
	The title concisely summarizes the main topic of the study and is	[Y]
	not too long (no more than 18 words). Words such as 'exploration',	
4	'research', 'analysis', 'observation', and 'investigation' are avoided.	
	The title does not start with 'The' and does not include any Arabic	
	numbers or uncommon abbreviations.	
5	A short running title is provided (no more than 6 words).	[Y]
	The authors' full family (sur)names and full/abbreviated first	[Y]
6	names are listed on the title page and are consistent with those	
	listed in the signed BPG Copyright License Agreement form.	
	The 'Author contributions' passage describes the specific	[Y]
	contribution(s) made by each author. The author's names are listed	
	in the following format: full family (sur)name followed by	
	abbreviated first and middles names.	
	e.g., "Wang CL and Liang L contributed equally to this work; Wang	
7	CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the	
	research study; Wang CL, Zou CC, Hong F and Wu XM performed	
	the research; Xue JZ and Lu JR contributed new reagents and	
	analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and	
	Wang CL, Liang L and Fu JF wrote the manuscript. All authors	
	have read and approve the final manuscript."	
	The 'Supported by' statement describes the source(s) of financial	[N]
8	support and includes the corresponding identification number(s)	
	and program ID(s) if available, and contains no spelling errors.	
	The 'Corresponding author' passage provides the corresponding	[Y]
0	author's full first and family (sur)names, abbreviated title (e.g., MD,	
9	PhD), affiliated institute's name and complete postal address	
	(including zip code) and e-mail (written in all lowercase), and	



	contains no spelling errors.	
	The Manuscript Tracking information (i.e., Received, Peer review	[Y]
10	started, First decision, Revised, Accepted, Article in press, and	
10	Published online) are provided along with the corresponding editor	
	and date for each item, and contain no spelling errors.	
	The Abstract section is formatted according to the article-specific	[Y]
	style (structured <i>vs</i> unstructured) and word count thresholds, as	
	follows:	
	Commentary, Frontier, Diagnostic Advances, Medical Ethics,	
	Minireview, Review, Therapeutics Advances, and Topic Highlight:	
11	Non-structured abstract that is no less than 200 words.	
11	Field of Vision, Case Report and Letter to the Editor:	
	Non-structured abstract that is no less than 150 words.	
	Research articles: Structured abstract with subsections for AIM (no	
	more than 20 words); METHODS (no less than 80 words); RESULTS	
	(no less than 120 words); and CONCLUSION (no more than 26	
	words).	
	The 'Key words' list provides 5-10 keywords that reflect the main	[Y]
12	content of the study. The first letter of each keyword is capitalized,	
	and each keyword is separated by a semicolon.	
	The "citation" contains authors' names and manuscript title. The	[Y]
13	name of the first author should be typed in bold letters; the family	
	(sur) name of all authors should be typed with the first letter	
	capitalized, followed by their abbreviated first and middle initials.	
	For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick	
	Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM,	
	Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes	
	mellitus increases the risk of gastric cancer: A meta-analysis. World J	



	Continued 2010 In success	
	<i>Gastroenterol</i> 2019; In press	
14	The 'Core tip' provides a summary (less than 100 words) of the	[Y]
	study that outlines the most innovative and important arguments	
14	and core contents of the paper and will serve to effectively attract	
	readers.	
	The 'INTRODUCTION' section clearly describes the relevant	[Y]
	background information for the study. Only the most relevant and	
	current (within the past 5 years) literature is cited, with the	
	exception of rare instances of seminal literature citations. All	
	technical terms and/or abbreviations are explained and/or defined,	
15	with the full name of abbreviations given upon first appearance in	
15	the text and the abbreviation presented in parentheses [i.e.,	
	"computed tomography (CT)"]. First-person pronouns (e.g., 'I',	
	'we') are used appropriately to clearly indicate the work performed	
	by the author(s). When weaknesses of previous studies are	
	described in the text to highlight the innovations related to the	
	current study, the information is presented carefully.	
	The 'MATERIALS AND METHODS' section clearly and accurately	[N]
16	describes all materials and methods used to obtain the data	
16	presented in the article and is adequate for a reader to repeat the	
	study.	
	The 'RESULTS' section concisely describes the observational and	[N]
	experimental results. Representative data and data that have	
17	scientific significance are emphasized. Data is presented in either	
	the text, a table or figure ( <i>i.e.</i> , chart, diagram, graph or image), but is	
	not repeated among each. Information presented in the tables and	
	figures clearly describes the trends, meaning, and inferences.	
	Results described in textual form are accurate, concise and clear.	
18	Statistical symbols are accurate. Statistical significance is expressed	[Y]
	as ${}^{a}P < 0.05$ , ${}^{b}P < 0.01$ ( $P > 0.05$ usually does not need to be denoted).	



		]
	If there are other series of <i>P</i> values, $^{c}P < 0.05$ and $^{d}P < 0.01$ are used,	
	and a third series of <i>P</i> values is expressed as $^{e}P < 0.05$ and $^{f}P < 0.01$ .	
	Statistical data is expressed as mean $\pm$ SD or mean $\pm$ SE.	
	The 'DISCUSSION' section (1) describes the main purpose and	[Y]
	hypothesis of the study; (2) summarizes the most important results;	
	(3) illustrates and explains the results (but does not simply repeat	
19	the data) and draws conclusions or inferences based on the results;	
19	(4) points out the limitations of the study and their impact on the	
	results, as well as proposes further advice on future research	
	topic(s) or direction(s); and (5) describes the theoretical significance	
	and practical value of the findings.	
	The 'ACKNOWLEDGEMENTS' section expresses gratitude to any	[N]
	individuals or organizations for technical support (i.e., providing	
	instrumentation, equipment or experimental materials, and/or	
20	assistance in experimental work), non-technical services ( <i>i.e.</i> , useful	
	inspiration, suggestions, guidance, or review), and/or any other	
	auxiliary work.	
	The 'ARTICLE HIGHLIGHTS' section provides comments for	[N]
21	original articles in accordance with the specified format.	
	The 'REFERENCES' section lists the references in the Vancouver	[Y]
	style. This style uses Arabic numeral in-text citations based on the	
	order of the first appearance of a source in the text. For citations	
22	where the author's name is indicated in the text, a superscript	
	number should be placed following the name ( <i>i.e.</i> ,, "Pang <i>et al</i> "). For	
	citations where no author is indicated, a superscript number should	
	be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup>	
	reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high	
	sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the	
	reference number is described in the text; for example, "The	
	experimental method used has been described in reference [8]." The	



	style of reference citations in tables is the same as that in the text	
	(e.g., Pan et al <sup>[2-5]</sup> , please see reference [8]).	
	Journal references have been verified to ensure that there are no	[Y]
	duplicate references and that the PMID numbers are correct. For	
	references not yet included in PubMed: the name of Chinese	
23	journals is spelled out using Chinese Pinyin, with the first letter of	
23	each word capitalized (e.g., Shijie Huaren Xiaohua Zazhi); the name of	
	journals in other languages are listed according to indexing	
	information retrieved from Google. Book references are presented	
	with all the information relevant to the electronic version.	
	The number of cited references is appropriate for the article type, as	[Y]
	follows:	
24	<u>Commentary:</u> no less than 50;	
24	<u>Review:</u> no less than 100;	
	<u>Article:</u> no less than 30/26;	
	Case Report and Letter to the Editor: no less than 1.	
	The ethics-related statements are provided in accordance with the	[Y]
25	manuscript type (e.g., Manuscript NoInstitutional review board	
	statement, Manuscript NoAnimal care and use statement, etc.).	
	The names of the peer reviewers and the scientific editor are present	[Y]
26	at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang	
	JL).	



27The order and numerical labeling of tables and figures is consistent with their appearance and presentation in the text. Symbols in tables (e.g., +, -, ×, +, +) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; F:, F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).[Y]31The revised peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The letter of peer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s)): (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form			
27tables (e.g., +, -, ×, *, *) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment A:; B:; C:; D:; F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		The order and numerical labeling of tables and figures is consistent	[Y]
27       footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F:         28       Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.       [Y]         29       The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.       [Y]         30       The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).       [Y]         31       The letter of peer-reviewers' comments is provided (file name: Manuscript NoReview; e.g., 870-Review(s)).       [Y]         32       The response letter is provided (file name: Manuscript NoAnswering reviewers).       [Y]         33       The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoBiostatistics statement); (4) Clinical trial registration statement; (5) Institutional review board approval form		with their appearance and presentation in the text. Symbols in	
<ul> <li>27 consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F:</li> <li>28 Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.</li> <li>29 The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.</li> <li>30 The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.</li> <li>31 The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).</li> <li>31 The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).</li> <li>32 The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form</li> </ul>		tables ( <i>e.g.</i> , +, -, $\times$ , $\div$ , *) correctly correspond to the definitions in the	
consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoBiostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	27	footnotes. Only one legend is provided for each multi-panel figure	
Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	<i></i>	consisting of color graphs, black and white graphs, or line graphs	
treatment. A:; B:; C:; D:; E:; F:28Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-reviewe(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoCollicical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		that depicts data of the same theme. For example: Figure 1	
Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.[Y]29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		Pathological changes in atrophic gastritis tissue before and after	
28graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoBiostatistics review certificate (file name: Manuscript MoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement); (5) Institutional review board approval form		treatment. A:; B:; C:; D:; E:; F:	
29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		Split pictures include flow charts, line graphs, histograms, and	[Y]
29The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]31The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	28	graphs including text. Unsplit pictures include meta-analysis	
29If the formation of the pervise of the		diagrams, PCR amplification curves, and survival curves.	
according to the peer-reviewers' comments.[Y]30The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.[Y]31The revised manuscript is provided (file name: Manuscript NoReview; <i>e.g.</i> , 870- Review).[Y]31The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); <i>e.g.</i> , 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; <i>e.g.</i> , 870-Answering reviewers).[Y]32The related ethics and relevant documents are provided, such as (1) approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript MoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	20	The author(s) highlighted the changes made to the manuscript	[Y]
<ul> <li>30 the changes made to the manuscript.</li> <li>The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).</li> <li>The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).</li> <li>The response letter is provided (file name: Manuscript NoAnswering reviewers).</li> <li>The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form</li> </ul>	29	according to the peer-reviewers' comments.	
the changes made to the manuscript.[Y]The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review).[Y]The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).[Y]The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement); (5) Institutional review board approval form	20	The responses to the peer-reviewers' comments are consistent with	[Y]
<ul> <li>NoReview; e.g., 870- Review).</li> <li>The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).</li> <li>The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).</li> <li>The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript</li> <li>NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement); (5) Institutional review board approval form</li> </ul>	30	the changes made to the manuscript.	
<ul> <li>The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).</li> <li>The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript</li> <li>NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement); (5) Institutional review board approval form</li> </ul>		The revised manuscript is provided (file name: Manuscript	[Y]
<ul> <li>Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).</li> <li>The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).</li> <li>The related ethics and relevant documents are provided, such as (1)</li> <li>Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form</li> </ul>		NoReview; e.g., 870- Review).	
Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement); (5) Institutional review board approval form	21	The letter of peer-reviewers' comments is provided (file name:	
NoAnswering reviewers; e.g., 870-Answering reviewers).The related ethics and relevant documents are provided, such as (1)Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript32NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	51	Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).	
The related ethics and relevant documents are provided, such as (1)[Y]Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript32NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		The response letter is provided (file name: Manuscript	
Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		NoAnswering reviewers; <i>e.g.</i> , 870-Answering reviewers).	
<ul> <li>approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form</li> </ul>		The related ethics and relevant documents are provided, such as (1)	[Y]
<ul> <li>form(s)); (2) Biostatistics review certificate (file name: Manuscript</li> <li>NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form</li> </ul>		Approved grant application form(s) or funding agency copy of any	
32 NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form	32	approval document(s) (file name: Manuscript NoGrant application	
name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		form(s)); (2) Biostatistics review certificate (file name: Manuscript	
trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form		NoBiostatistics statement); (3) Conflict-of-interest statement (file	
registration statement); (5) Institutional review board approval form		name: Manuscript NoConflict-of-interest statement); (4) Clinical	
		trial registration statement (file name: Manuscript NoClinical trial	
or document (file name: Manuscript NoInstitutional review board		registration statement); (5) Institutional review board approval form	
		or document (file name: Manuscript NoInstitutional review board	



	statement); (6) Institutional animal care and use committee	
	approval form or document (file name: Manuscript	
	NoInstitutional animal care and use committee statement), and (7)	
	Signed informed consent form(s) or document(s) (file name:	
	Manuscript NoInformed consent statement).	
	All authors signed the BPG Copyright license agreement form (file	[Y]
33	name: Manuscript NoCopyright license agreement; <i>e.g.</i> ,	
	870-Copyright license agreement).	
	The language certificate provided by authors who are non-native	[Y]
34	speakers of English meets the BPG requirements (file name:	
	Manuscript NoLanguage certificate; <i>e.g.</i> , 870-Language certificate).	
	The photos licensed in the Agreement for Use of Personal Photos	[N]
	are consistent with those in the paper (file name: Manuscript	
35	NoAgreement for use of personal photos; e.g., 870-Agreement for	
	use of personal photos).	
	This document (Checklist of Responsibilities for Scientific Editors)	[Y]
36	has been saved under the file name: manuscript NoScientific	
	editor work list ( <i>e.g.</i> , 870-Scientific editor work list).	
	A CrossCheck investigation (an effective tool for detecting unoriginal	[Y]
	content, enabling our editors to preserve the journal's integrity and	
	the authors' copyright) has been performed for the manuscript via	
	the website: http://www.ithenticate.com/. The results document	
	contains the following information for the manuscript: "Name of	
37	journal", "Manuscript No.", "Columns", "Title" and "Author list".	
	The Figure of the CrossCheck results is saved in JPEG format (.jpg) at	
	1440 $\times$ 680 pixel resolution. The PDF of the <i>CrossCheck</i> results has	
	been saved under the file name: manuscript No CrossCheck report	
	(e.g., 870-CrossCheck report). The Google searches have also been	
	performed to further ensure publication of original content.	
38	The text of the manuscript is typed in Book Antiqua font, 12 pt, with	[Y]
00	The text of the manuscript is typed in book fundqua fond, 12 pt, whit	



	1.5 line spacing.	
Responsibilities of scientific editors	The primary responsibilities of our scientific editors include carefully checking the entire manuscript and all accompanying materials for: (1) errors in spelling, grammar, punctuation and wording; (2) suitability of tables, figures, figure data and legends; (3) accurate and appropriate presentation of symbols ( <i>e.g.</i> +, -, ×, $\div$ , %, *) in tables and figures; and (4) complete and comprehensive revision of the manuscript	
Publication process	according to the reviewers' comments. Manuscript reception and registration $\rightarrow$ Initial review by scientific editor $\rightarrow$ Peer review $\rightarrow$ End of peer review $\rightarrow$ First round of meeting evaluation $\rightarrow$ To be accepted $\rightarrow$ Revision by the author(s) $\rightarrow$ Second round of meeting evaluation $\rightarrow$ To be accepted/revised/rejected $\rightarrow$ Final review by the Editor-in-Chief (final quality control for academic content and language quality) $\rightarrow$ Final acceptance and charging of publication fee $\rightarrow$ Language editing $\rightarrow$ Production $\rightarrow$ Proofreading by scientific editor $\rightarrow$ Proofreading by deputy editor $\rightarrow$ Final review by Editor-in-Chief $\rightarrow$ Release of online open-access papers in electronic form on the BPG website $\rightarrow$ Release of online papers on PubMed Central $\rightarrow$ Delivery of high-quality PDF reprints to the author(s) $\rightarrow$ End of the publication process.	